Memantine
Namenda — an uncompetitive open-channel NMDA receptor antagonist
Memantine (Namenda — an uncompetitive open-channel NMDA receptor antagonist) is a cognitive & mood research compound. A low to moderate affinity uncompetitive open-channel NMDA receptor antagonist, which means it can only enter a channel glutamate has already opened and leaves again quickly. That combination blocks the steady background leak of a chronically over-activated receptor while stepping aside for the brief bursts that carry a signal. It is the only widely used dementia drug acting on the glutamate side rather than by raising acetylcholine, which is why it is studied in combination with the cholinesterase inhibitors rather than against them.
Memantine quick facts
| Route | Oral |
| Frequency | Per prescription · Per prescription |
| Half-life | 60-80 hrs — roughly two weeks to steady state, and renal clearance falls about 80% at urine pH 8 |
| Forms | Oral |
| Evidence level | Approved for moderate to severe Alzheimer's dementia. In the largest pooled dataset it did not reach the reviewers' own threshold for a clinically important effect as a single agent. |
The approved indication is moderate to severe Alzheimer's dementia, which is not why most people reading a nootropics catalog would buy it. Two things are worth knowing before anything else. In an individual-patient network meta-analysis of 80 trials and 21,138 people, this drug alone did not clear the 1.40-MMSE-point threshold its own reviewers set for clinical importance. And its renal clearance falls by about 80% when urine goes alkaline at pH 8 — which is what sodium bicarbonate loading before hard training does — on a molecule that already takes two weeks to reach steady state. Prescription medicine, no buy button.
How Memantine works
A low to moderate affinity uncompetitive open-channel NMDA receptor antagonist, which means it can only enter a channel glutamate has already opened and leaves again quickly. That combination blocks the steady background leak of a chronically over-activated receptor while stepping aside for the brief bursts that carry a signal. It is the only widely used dementia drug acting on the glutamate side rather than by raising acetylcholine, which is why it is studied in combination with the cholinesterase inhibitors rather than against them.
Proposed benefits
Researched for focus, memory, neuroprotection, mood and stress resilience.
Where to get Memantine
Buy Memantine at RUPharma →Approved for moderate-to-severe Alzheimer's dementia. Its own label does not claim it changes the course of the disease.
About half of it leaves the body unchanged through the kidney, and the label lowers the target dose in severe renal impairment. That makes kidney function the number that decides the dose — and it is a number most people have never looked at.
Order these through my Marek link →The evidence for Memantine
Graded by what exists behind each claim.
✅ Clinically validated
- Approved for moderate to severe Alzheimer's dementia, and that is the whole indication — not mild disease, not age-related forgetfulness. An individual-patient network meta-analysis of 80 randomized trials in 21,138 adults set 1.40 MMSE points as its threshold for a clinically important difference and reports that every regimen cleared it EXCEPT single-agent rivastigmine, galantamine and memantine (Veroniki 2022).
- A 2026 Bayesian network meta-analysis of 125 trials in more than 30,000 people put memantine at a standardized mean difference of 0.24 and donepezil at 0.21 — while aerobic exercise scored 0.55 and cognitive training 0.45 in the same network (Li 2026). The authors are careful that the non-drug arms are short-term and adjunctive rather than substitutes.
- Nobody has ever tested it in cognitively normal adults. Every participant in both syntheses carried a dementia diagnosis.
📊 Correlative data
- The Cochrane review of stopping these drugs pooled six trials and 759 participants and states that no trial assessed withdrawal of memantine alone (Parsons 2021). Anyone starting it without a prescriber has no published basis for deciding when or how to stop.
- The 2025 dementia guideline recommends it strongly for moderate to severe Alzheimer's disease and separately from the cholinesterase inhibitors, because it acts on a different transmitter system (Kim 2025).
🧪 Theoretical / extrapolated
- A low-to-moderate affinity uncompetitive open-channel NMDA antagonist: it can only enter a channel glutamate has already opened and leaves again quickly, which blocks a chronic background leak while stepping aside for signal-carrying bursts.
- The interaction nobody warns this audience about. Its label states renal clearance falls about 80% under alkaline urine at pH 8. Sodium bicarbonate loading before hard intervals does exactly that, on a drug with a 60-80 hour half-life — so the result is accumulation, and the presentation of too much of it is confusion.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Memantine actually does
The mechanism is a filter, not a switch, and the whole drug follows from that. The label states it plainly: memantine acts as a low to moderate affinity uncompetitive open-channel NMDA receptor antagonist Memantine label 2025. Uncompetitive means it can only enter a channel that glutamate has already opened. Low affinity means it leaves again quickly. Put those together and you get a molecule that blocks the steady background leak of a chronically over-activated receptor while still stepping aside for the brief high-amplitude bursts that carry a signal. High-affinity blockers of the same channel do not do this, which is why one of them became a dissociative drug of misuse and this one did not.
What it is approved for, and it is narrower than the shelf it is sold on. The indication is moderate to severe dementia of the Alzheimer's type Memantine label 2025. Not mild. Not age-related forgetfulness, not brain fog, and not the reason most people reading a nootropics catalog would buy a $45 box of 10 mg tablets. It is a prescription medicine, and this page carries no purchase route for that reason.
It is not a cholinesterase inhibitor, and the difference matters. Donepezil, galantamine and rivastigmine all raise acetylcholine by blocking the enzyme that clears it. Memantine touches none of that. It is the only widely used dementia drug acting on the glutamate side, which is why the combination has been studied as a combination rather than as a duplication, and why guideline recommendations for the two classes are written separately Kim 2025.
Cell, rodent, human — and where it stops
Two large syntheses, and neither flatters this molecule alone. Veroniki 2022 is an individual-patient-data network meta-analysis of 80 randomized trials covering 21,138 adults with Alzheimer's dementia. Donepezil improved Mini-Mental State Examination score by 1.41 points (95% CI 0.51 to 2.32) against placebo, and donepezil plus memantine by 2.57 (0.07 to 5.07). The authors set 1.40 MMSE points as their threshold for a clinically important difference, and state that every regimen cleared it except single-agent oral rivastigmine, galantamine and memantine. On the largest pooled dataset available, this drug alone did not reach the bar its own reviewers set.
The newer network meta-analysis agrees on the size and adds an uncomfortable comparison. Li 2026 synthesized 125 randomized phase II and III trials in more than 30,000 people. Memantine returned a standardized mean difference of 0.24 (95% credible interval 0.13 to 0.35) and donepezil 0.21. In the same network, aerobic exercise scored 0.55 and cognitive training 0.45. The authors are careful that the non-drug arms are short-term and adjunctive rather than substitutes, and the ranking is still the ranking: on that scale, two behaviors outscored every molecule in the analysis.
What the evidence does support is specific. Both syntheses and the 2025 guideline Kim 2025 agree the effect is larger in moderate to severe disease and that combination with a cholinesterase inhibitor outperforms either drug alone. Nobody in this literature is measuring healthy cognition. Every participant in every trial above carried a dementia diagnosis, and a reader arriving from a nootropics search sits outside the population that generated all of it.
And the Cochrane review found a hole exactly where a buyer wants an answer. Parsons 2021 pooled six trials, 759 participants on stopping these drugs and reports in its own conclusions that no trial assessed withdrawal of memantine alone and that there is no evidence to guide discontinuing it. Anyone who starts this molecule without a prescriber has no published basis for deciding when or how to stop.
Memantine pharmacokinetics — how much of it actually gets in
The half-life is the most useful number on this page. Terminal elimination half-life is 60 to 80 hours Memantine label 2025. Five half-lives to steady state puts full exposure at roughly 12 to 17 days after a dose is set. Anyone judging this drug in week one is judging perhaps half the concentration they will eventually carry, and the four-week upward titration on the label follows from that arithmetic rather than from caution.
It is a kidney drug wearing a brain drug's label. About 48% of a dose leaves unchanged in urine, plasma protein binding is a low 45%, and the label states CYP450 enzymes are not significantly involved in its metabolism Memantine label 2025. That is good news in one direction — the large class of CYP-mediated interactions mostly does not apply. It is bad news in another, because the elimination route that does matter is the one people lose without noticing, and the label carries a reduced target dose of 5 mg twice daily in severe renal impairment.
The interaction nobody in this readership is warned about. Renal clearance falls by about 80% under alkaline urine conditions at pH 8 Memantine label 2025, because the molecule is a cation whose tubular reabsorption rises as urine alkalinizes. Sodium bicarbonate loading before hard intervals is a mainstream ergogenic practice in exactly this audience and does precisely that to urine pH. A drug already sitting on a 60 to 80 hour half-life, handed an 80% clearance reduction, accumulates rather than spikes — and the presentation of too much of it is confusion, which is also the symptom it was taken to fix.
Absorption is unremarkable, and that is worth saying. Peak concentrations arrive at roughly 3 to 7 hours and the drug is highly absorbed orally Memantine label 2025, so there is no fasting window to get right and no food effect to work around. Very little else on this page is that simple.
What would have to be true, and how you would know it was not
Three predictions, and the first decides whether a reader should be taking this at all.
1. A cognitive score, before and at 12 weeks. MMSE or MoCA, administered by the same person at the same time of day. The pooled effect in dementia is 1.41 MMSE points for the best regimen in the network and less than that for this drug alone Veroniki 2022. In a person without dementia, prediction: no change beyond test-retest variation, which on the MMSE is comfortably larger than the effect being looked for. That is the falsification, it costs nothing, and it has never been run in a healthy adult.
2. Creatinine and estimated GFR at baseline. Not because the drug harms kidneys — no such claim exists — but because the kidney sets the exposure. Half the dose leaves unchanged in urine and the label lowers the target dose in severe impairment Memantine label 2025. Taking this without knowing your own filtration rate is guessing at your own concentration.
3. Against the drug, and testable in one experiment. If the mechanism is genuine block of chronic excitotoxic signaling, the effect should be absent where there is no chronic excitotoxic signaling. Give it to healthy adults, measure trail making and reaction time at steady state rather than at day 3, and the prediction is flat. Nobody has published that trial, and the two network meta-analyses above contain no healthy participants at all.
What nobody has tested yet
Nobody has run a discontinuation trial of memantine on its own. The Cochrane review says so in its own conclusions Parsons 2021: six trials, 759 participants, all on cholinesterase inhibitors, and no evidence to guide stopping this drug. For a molecule taken for years, on a 60 to 80 hour half-life, that is a strange gap, and it is the one that most affects somebody who has already started.
Nobody has tested it in cognitively normal adults. That is the population buying it from a catalog. Every participant in the 21,138 of Veroniki 2022 and the 30,000-plus of Li 2026 had a diagnosis. The trial is straightforward and its absence means every claim made for this drug outside dementia is extrapolation across a population boundary rather than evidence.
The urine-pH interaction has never been quantified in a person doing the thing that causes it. The 80% clearance reduction at pH 8 is a label statement Memantine label 2025. What nobody has published is what happens to plasma concentration in an athlete who alkalinizes deliberately and repeatedly while on a drug at steady state. That is a pharmacokinetic study with a dozen participants, and it does not exist.
Extrapolation, labeled as such. If the benefit really concentrates in moderate to severe disease Kim 2025, effect size should scale inversely with baseline cognition, which is measurable in existing trial datasets and has been examined only by subgroup. And if the network ranking is real Li 2026, then a trial randomizing this drug against structured aerobic exercise on one cognitive endpoint is the most informative study anybody could run in this field. Nobody has run it.
Memantine — its own safety story, not its class's
Three things this molecule owns that a class warning does not cover.
The common adverse reactions are the symptoms it is taken for. The label lists dizziness, headache, confusion and constipation at 5% or more and above placebo Memantine label 2025. Confusion sits on both sides of the ledger. Somebody self-medicating for perceived cognitive decline, with no baseline test and no prescriber, cannot distinguish the drug failing from the drug causing the thing being watched — and on a 60 to 80 hour half-life that feedback loop takes weeks to close.
Kidney function sets the dose and most people do not know theirs. Roughly half the drug is cleared unchanged renally and the label specifies a lower target in severe impairment Memantine label 2025. Reduced filtration is common, frequently silent, and more likely in the age group most drawn to this drug. That is a dosing decision needing a blood test and a prescriber, and it is the main reason no purchase route appears here.
Stopping is not a solved problem. Cochrane found no trial of withdrawing memantine alone Parsons 2021, while its finding for the cholinesterase inhibitors was that stopping may leave people cognitively and functionally worse than continuing. Nothing in that review licenses a claim about memantine withdrawal in either direction. The honest statement is that the exit from this drug is unstudied, and that is worth knowing before the entrance.
Sources read for this page
- U.S. Food and Drug Administration. Memantine hydrochloride tablets - full prescribing information, including the uncompetitive open-channel NMDA antagonist statement, the 60-80 hour terminal half-life, the renal clearance and urine pH section and the severe renal impairment dose. DailyMed, U.S. National Library of Medicine; Carlsbad Technology Inc. label version 2, revised February 2025
- Veroniki AA, Ashoor HM, Rios P, et al. Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis. BMJ Open 2022 · PMID 35473731
- Li Y, Li L, Yang Q, Xiong J. Comparative Efficacy and Safety of Cholinesterase Inhibitors and NMDA Receptor Antagonists in Alzheimer's Disease: A Systematic Review and Network Meta-Analysis. Current Alzheimer Research 2026 · PMID 42099163
- Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward SA, Hughes C. Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database of Systematic Reviews 2021 · PMID 35608903
- Kim Y, Kang DW, Kim GH, et al. (Korean Dementia Association). Clinical Practice Guidelines for Dementia: Recommendations for Cholinesterase Inhibitors and Memantine. Dementia and Neurocognitive Disorders 2025 · PMID 39944527
Memantine — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Memantine moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
- Dose range and how to work up to it
- When to take it, and why that window
- Cycle length
- Time off between cycles
- Fasted or fed, and when in the day
- Coach Cam's personal notes
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Everything above is free and stays free. Skool is where it becomes a plan — Memantine in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Memantine
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Memantine — frequently asked questions
What is Memantine?
Memantine (Namenda — an uncompetitive open-channel NMDA receptor antagonist) is a cognitive & mood research compound. A low to moderate affinity uncompetitive open-channel NMDA receptor antagonist, which means it can only enter a channel glutamate has already opened and leaves again quickly. That combination blocks the steady background leak of a chronically over-activated receptor while stepping aside for the brief bursts that carry a signal. It is the only widely used dementia drug acting on the glutamate side rather than by raising acetylcholine, which is why it is studied in combination with the cholinesterase inhibitors rather than against them.
Where can I find Memantine dosing and protocols?
Dosing, the reconstitution calculator and Coach Cam's full Memantine protocol are available to members inside Skool. This public page covers what Memantine is, how it works and the evidence.
What is the half-life of Memantine?
Memantine has an approximate half-life of 60-80 hrs — roughly two weeks to steady state, and renal clearance falls about 80% at urine pH 8, which is part of what determines how often it's dosed.
What's the evidence behind Memantine?
Current evidence level: Approved for moderate to severe Alzheimer's dementia. In the largest pooled dataset it did not reach the reviewers' own threshold for a clinically important effect as a single agent.. Memantine is offered for research purposes only and is not an approved medicine.
What Memantine is used for
Memantine appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.